Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FibroBiologics, Inc.FBLG · Entity 7875 | Chief Financial Officer | May 04, 2026 | May 04, 2026 |
| HYPERDYNAMICS CORPHDYN · Entity 173495 | Interim CFO | July 17, 2017 | July 27, 2017 |
| Virax Biolabs Group LtdVRAX · Entity 8504 | Chief Financial Officer | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FibroBiologics, Inc.
Report date May 04, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2036-05-04 | Direct | 61,607 |
Reported balance
After 2026-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 61,607 · Balance 61,607 F1: On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.
HYPERDYNAMICS CORP
Report date July 17, 2017 · Filed July 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,651 |
Reported balance
After 2017-07-17 transaction · row 1
1 source rowRow 1 · 2017-07-17 · Purchase · Acquired 34,248 · Balance 73,651 |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2019-07-16 | Direct | 25,686 |
Reported balance
After 2017-07-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-17 · Grant · Acquired 25,686 · Balance 25,686 |
Virax Biolabs Group Ltd
Report date March 18, 2026 · Filed March 18, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 4, 2026 23:00 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 61,607 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-26-021173 · ownership.xml · derivative · entry 1 Davis Jason · CIK 0001443533 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,607 Underlying: Common Stock · 61,607 shares Expires 2036-05-04 F1 · derivative.exercise_date: On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 13:00 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | PurchaseCommon Stock | 70,000 | $0.41 | $28,973.00 |
DisclosureSEC source: 0001493152-26-008646 · ownership.xml · nonDerivative · entry 1 Davis Jason · CIK 0001443533 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:03 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001641172-25-014512 · ownership.xml · derivative · entry 1 Davis Jason · CIK 0001443533 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-06-08 F1 · derivative.exercise_date: On June 9, 2025, the reporting person was granted an option to purchase 450,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. Read SEC document |
| July 17, 2017 Filed Jul 27, 2017 18:14 UTC | HYPERDYNAMICS CORP HDYN · Entity 173495 | GrantCommon Stock Warrants (right to buy) · Derivative | 25,686 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001104659-17-047469 · a4.xml · derivative · entry 2 Davis Jason · CIK 0001443533 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,686 Underlying: Common Stock · 25,686 shares Expires 2019-07-16 Read SEC document |
| July 17, 2017 Filed Jul 27, 2017 18:14 UTC | HYPERDYNAMICS CORP HDYN · Entity 173495 | PurchaseCommon Stock | 34,248 | $1.46 | $50,002.08 |
DisclosureSEC source: 0001104659-17-047469 · a4.xml · nonDerivative · entry 1 Davis Jason · CIK 0001443533 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,651 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:07 UTC | HYPERDYNAMICS CORP HDYN · Entity 173495 | GrantCommon Stock | 5,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-043650 · a4.xml · nonDerivative · entry 1 Davis Jason · CIK 0001443533 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,403 F1 · shares: The reporting person received award of restricted stock, subject to restrictions that will lapse on October 1, 2017. Read SEC document |
| June 06, 2017 Filed Jun 20, 2017 15:47 UTC | HYPERDYNAMICS CORP HDYN · Entity 173495 | GrantIncentive Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001104659-17-040418 · a4.xml · derivative · entry 1 Davis Jason · CIK 0001443533 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2022-06-05 F1 · derivative.exercise_date: 50% of this stock option will vest on December 31, 2017, and the remaining 50% will vest on June 6, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.